SequelSEC

ACRO BIOMEDICAL CO., LTD. ACBM

Services-Amusement & Recreation Services · CIK 0001622996 · Fiscal year ends 1231

Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$154.02K
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

ACRO BIOMEDICAL CO., LTD. (ACBM) reported revenue of $0 and net income of -$101.15K for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ACRO BIOMEDICAL CO., LTD.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Amusement & Recreation Services.

Income

ACRO BIOMEDICAL CO., LTD. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312019-09-302018-09-302017-09-30
Revenue$0$0$0$658.50K$1.20M$687.96K$193.54K$1.35M$8.01M$510.00K
Cost of revenueUnavailableUnavailable$0$518.00K$938.00K$528.56K$181.44K$1.22M$7.18M$459.00K
Gross profitUnavailableUnavailable$0$140.50K$259.50K$159.40K$12.10K$135.40K$833.40K$51.00K
Operating income-$154.02K-$37.96K-$8.80M-$15.87M-$7.69M-$130.46K-$422.75K-$441.55K$515.55K-$2.25K
Net income-$101.15K-$42.30K-$8.81M-$15.87M-$7.70M-$117.45K-$371.60K-$370.75K$419.66K-$2.25K
Research & developmentUnavailable$0$4.79M$10.08M$5.29MUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 60.04Mshares 60.04Mshares 60.04Mshares 60.04Mshares 53.84Mshares 47.76MUnavailableUnavailableUnavailableUnavailable
Pretax income-$101.15K-$42.30K-$8.81M-$15.87MUnavailable-$135.54K-$424.73K-$443.82K$511.89K-$2.25K
Income tax expense$0$0$0$0$0-$18.09K-$53.13K-$73.07K$92.23K$0
Diluted EPS$0.00$0.00$-0.15$-0.26UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$154.02K$37.96K$3.52M$5.93M$2.67M$289.87K$434.85K$576.95K$317.85K$53.25K
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ACRO BIOMEDICAL CO., LTD. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312019-09-302018-09-302017-09-30
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailable$18.12K$911$1.47K$1.15K$36.81K
Total assets$14.10K$31.97K$58.46K$687.49K$761.08K$998.05K$932.13K$1.07M$1.48M$548.31K
Current assets$14.10K$5.08K$1.63K$657.54K$706.42K$973.35K$879.47K$1.07M$1.48M$548.31K
Total liabilitiesUnavailable$326.95K$315.47K$201.12K$117.37K$312.18K$133.89K$195.79K$240.68K$36.98K
Current liabilities$401.06K$326.95K$288.58K$201.12K$91.65K$312.18K$111.54K$195.79K$240.68K$36.98K
Total equity incl. NCI-$386.96K-$294.97K-$257.01K$486.37K$643.71K$685.87K$798.24K$873.67K$1.24M$511.33K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable$0$938.00K$878.56K$1.06M$1.15M$481.00K
Accounts receivableUnavailableUnavailable$0$638.50K$598.00K$0UnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$55.55KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

ACRO BIOMEDICAL CO., LTD. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312019-09-302018-09-302017-09-30
Operating cash flow-$196.30K-$36.69K-$15.45K-$147.48K$299.34K-$199.46K-$59.71K$79.69K-$140.42K-$463.34K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$199.92K$36.79K$9.97K$58.08K-$222.21K$216.67K$23.01K-$79.37K$104.76K$497.62K
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailable$17.21K-$36.70K$324-$35.66K$34.28K
Stock-based compensationUnavailable$0$8.06M$15.71M$7.65M$0$148.40K$300.09K$7.41KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

ACRO BIOMEDICAL CO., LTD. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312019-09-302018-09-302017-09-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable21.3%21.7%23.2%6.2%10.0%10.4%10.0%
Operating marginUnavailableUnavailableUnavailable-2410.0%-642.5%-19.0%-218.4%-32.6%6.4%-0.4%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable2386.1%638.9%0.0%76.7%22.2%0.1%Unavailable
Current ratio0.04x0.02x0.01x3.27x7.71x3.12x7.88x5.46x6.14x14.83x
Revenue YoY growthUnavailableUnavailable-100.0%-45.0%74.1%255.5%Unavailable-83.1%1471.5%Unavailable
Net marginUnavailableUnavailableUnavailable-2410.2%-642.8%-17.1%-192.0%-27.4%5.2%-0.4%
R&D / revenueUnavailableUnavailableUnavailable1530.8%441.4%UnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable18.0%Unavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ACBM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-K · Filed 2025-07-24View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.